Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Grass Pollen

Immunotherapy is a specific treatment for allergic diseases. Unlike conventional pharmacological treatment, immunotherapy is the only treatment that could modify the natural course of allergic disease. This is a prospective double-blind placebo controlled study with two arms of treatment in an up-dosing cluster regimen for 4 weeks.

Inclusion criteria

• Informed consent, signed by the subject.
• Clinical History of moderate to severe rhinitis/rhinoconjunctivitis lasting for at least 2 consecutive years, with or without episodic asthma, caused by allergy to grass pollen.
• Patient of both gender aged from 18 up to 55
• Symptoms that coincide with allergy to grass pollen
• Sensitivity to grass pollen, diagnosed through a positive skin reaction to Phleum pratense: Positive prick test and /or Specific IgE to P.pratense >0,7KU/L Patients included must be mono-sensitised or, in the case of poly-sensitisation, sensitivity to p.pratense pollen should be considered as the only relevant aspect of their condition from the clinical standpoint.
• Patients who are able to comply with the dose regime

Exclusion criteria

• Patient with mild Rhinitis/rhinoconjunctivitis
• Relevant sensitivity to another perennial allergen
• Use of immunotherapy during the last four years
• Treatment with B. Blocking agents
• Patient suffering from some pathology in which adrenalin was contraindicated
• Subject suffers from a serious medical condition, which would interference the treatment and follow up of the subject in the study
• Subject suffers from autoimmune disease(thyroiditis, lupus, etc.)
• Conditions in which the patient can not offer full co-operation and significant psychiatric disorders.
• Intolerance to aspirin
• Pregnant women or with pregnancy risk and breast-feeding